Business, energy, technology, markets and global industry news from Business News Today

rare cancer therapy

PharmaDeviceNews rare cancer therapy
Representative image: Citius Oncology’s Lymphir commercialisation push highlights the growing pressure on rare cancer biotech firms to turn FDA approvals and fresh funding into real-world treatment adoption.
Pharma & Biotech

Citius Oncology raises $36.5m, but can Lymphir convert rare cancer approval into commercial traction?

Lymphir has funding and FDA approval. Citius Oncology now faces the harder test of turning rare cancer access into real adoption.

Read More